Cargando…

Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617

While treatment options are available, excessive daytime sleepiness (EDS) remains a significant unmet medical need for many patients. Relatively little rodent behavioural pharmacology has been conducted in this context to assess potential pro-vigilant compounds for their ability to restore functiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Loomis, Sally, McCarthy, Andrew, Baxter, Christopher, Kellett, Daniel O., Edgar, Dale M., Tricklebank, Mark, Gilmour, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600478/
https://www.ncbi.nlm.nih.gov/pubmed/25902875
http://dx.doi.org/10.1007/s00213-015-3936-8
_version_ 1782394425929891840
author Loomis, Sally
McCarthy, Andrew
Baxter, Christopher
Kellett, Daniel O.
Edgar, Dale M.
Tricklebank, Mark
Gilmour, Gary
author_facet Loomis, Sally
McCarthy, Andrew
Baxter, Christopher
Kellett, Daniel O.
Edgar, Dale M.
Tricklebank, Mark
Gilmour, Gary
author_sort Loomis, Sally
collection PubMed
description While treatment options are available, excessive daytime sleepiness (EDS) remains a significant unmet medical need for many patients. Relatively little rodent behavioural pharmacology has been conducted in this context to assess potential pro-vigilant compounds for their ability to restore functional capacity following experimentally induced sleep loss. Male Wistar rats were prepared for electroencephalographic (EEG) recording and subject to 11 h of sleep restriction using a biofeedback-induced cage rotation protocol. A simple response latency task (SRLT) was used to behaviourally index sleep restriction and the effects of pro-vigilant compounds: modafinil, d-amphetamine, caffeine, and the mGlu5-positive allosteric modulator LSN2814617. Sleep restriction resulted in a consistent, quantified loss of non-rapid eye movement (NREM) and REM sleep that impaired SRLT performance in a manner suggestive of progressive task disengagement. In terms of EEG parameters, all compounds induced wakefulness. Amphetamine treatment further decreased SRLT performance capacity, whereas the other three compounds decreased omissions and allowed animals to re-engage in the task. Caffeine and modafinil also significantly increased premature responses during this period, an effect not observed for LSN2814617. While all compounds caused compensatory sleep responses, the magnitude of compensation observed for LSN2814617 was much smaller than would be predicted to result from the prolongation of wakefulness exhibited. Using simple response latencies to index performance, an mGlu5 PAM dramatically increased wakefulness and improved functional capacity of sleep-restricted animals, without eliciting a proportionate compensatory sleep response. This effect was qualitatively distinct from that of amphetamine, caffeine and modafinil. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00213-015-3936-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4600478
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-46004782015-10-16 Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617 Loomis, Sally McCarthy, Andrew Baxter, Christopher Kellett, Daniel O. Edgar, Dale M. Tricklebank, Mark Gilmour, Gary Psychopharmacology (Berl) Original Investigation While treatment options are available, excessive daytime sleepiness (EDS) remains a significant unmet medical need for many patients. Relatively little rodent behavioural pharmacology has been conducted in this context to assess potential pro-vigilant compounds for their ability to restore functional capacity following experimentally induced sleep loss. Male Wistar rats were prepared for electroencephalographic (EEG) recording and subject to 11 h of sleep restriction using a biofeedback-induced cage rotation protocol. A simple response latency task (SRLT) was used to behaviourally index sleep restriction and the effects of pro-vigilant compounds: modafinil, d-amphetamine, caffeine, and the mGlu5-positive allosteric modulator LSN2814617. Sleep restriction resulted in a consistent, quantified loss of non-rapid eye movement (NREM) and REM sleep that impaired SRLT performance in a manner suggestive of progressive task disengagement. In terms of EEG parameters, all compounds induced wakefulness. Amphetamine treatment further decreased SRLT performance capacity, whereas the other three compounds decreased omissions and allowed animals to re-engage in the task. Caffeine and modafinil also significantly increased premature responses during this period, an effect not observed for LSN2814617. While all compounds caused compensatory sleep responses, the magnitude of compensation observed for LSN2814617 was much smaller than would be predicted to result from the prolongation of wakefulness exhibited. Using simple response latencies to index performance, an mGlu5 PAM dramatically increased wakefulness and improved functional capacity of sleep-restricted animals, without eliciting a proportionate compensatory sleep response. This effect was qualitatively distinct from that of amphetamine, caffeine and modafinil. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00213-015-3936-8) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-04-24 2015 /pmc/articles/PMC4600478/ /pubmed/25902875 http://dx.doi.org/10.1007/s00213-015-3936-8 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Investigation
Loomis, Sally
McCarthy, Andrew
Baxter, Christopher
Kellett, Daniel O.
Edgar, Dale M.
Tricklebank, Mark
Gilmour, Gary
Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617
title Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617
title_full Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617
title_fullStr Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617
title_full_unstemmed Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617
title_short Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617
title_sort distinct pro-vigilant profile induced in rats by the mglur5 potentiator lsn2814617
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600478/
https://www.ncbi.nlm.nih.gov/pubmed/25902875
http://dx.doi.org/10.1007/s00213-015-3936-8
work_keys_str_mv AT loomissally distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617
AT mccarthyandrew distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617
AT baxterchristopher distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617
AT kellettdanielo distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617
AT edgardalem distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617
AT tricklebankmark distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617
AT gilmourgary distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617